Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
27 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting U.S. CTEPH Registry
Conditions: Chronic Thromboembolic Pulmonary Hypertension (CTEPH);   Pulmonary Hypertension
Intervention:
2 Recruiting Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Conditions: Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Heart Diseases;   Cardiovascular Diseases;   Arteriosclerosis;   Arterial Occlusive Diseases;   Vascular Diseases
Intervention: Procedure: CorPath-assisted Percutaneous Coronary Intervention
3 Recruiting Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage
Conditions: Vasospasm, Intracranial;   Subarachnoid Hemorrhage
Interventions: Device: Extraventricular Drain;   Device: Lumbar Drain
4 Recruiting PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial
Condition: Portopulmonary Hypertension
Interventions: Drug: Macitentan;   Other: Placebo
5 Recruiting Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Condition: Abdominal Aortic Aneurysm (AAA)
Intervention: Device: Nellix System
6 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention
7 Recruiting Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension
Conditions: Glaucoma, Open-Angle;   Ocular Hypertension
Interventions: Drug: Bimatoprost sustained-release;   Other: Sham;   Drug: Timolol;   Drug: Timolol Vehicle (placebo)
8 Recruiting The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Macitentan;   Drug: Tadalafil;   Drug: Selexipag
9 Recruiting A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ubenimex;   Other: placebo
10 Recruiting Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Condition: Ischemic Attack, Transient
Interventions: Drug: Clopidogrel;   Drug: placebo
11 Recruiting Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke
Condition: Stroke
Interventions: Device: Telerehabilitation Therapy;   Behavioral: In-Clinic Therapy
12 Recruiting Women's Heart Attack Research Program- Imaging Study
Condition: Myocardial Infarction
Interventions: Device: OCT;   Other: CMR
13 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402
14 Recruiting Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Conditions: Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
15 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
16 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
17 Recruiting Post Market Surveillance Study of the Wingspan Stent System
Condition: Intracranial Atherosclerosis
Intervention: Device: Wingspan Stent System
18 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
19 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
20 Recruiting Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Conditions: Stroke, Acute;   Cerebral Infarction
Interventions: Procedure: Endovascular Thrombectomy;   Device: Trevo Retriever;   Device: Solitaire™ FR Revascularization Device;   Device: Penumbra thrombectomy system;   Device: Covidien MindFrame Capture Revascularization Device

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.